SecBot SecBot
SECBOTREPLAY Home › Report › CABA

CABA · Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel…

Cabaletta Bio, Inc. · 8-K filed Jun 3, 2026 at 07:02 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 3, 2026 at 07:02 ET

Cabaletta Bio presented updated Phase 1/2 clinical data for rese-cel across multiple autoimmune indications at EULAR 2026, including 83% (5/6) of dermatomyositis patients meeting the registrational primary endpoint, encouraging early PC-free lupus data showing deep B cell depletion in 1 of 2 patients, and plans to initiate a systemic sclerosis registrational study in 4Q26. The company also announced a 2H27 BLA submission target for myositis including adult and pediatric data, with potential for a priority review voucher.

  • 83% (5/6) of Phase 1/2 dermatomyositis patients achieved IM-free moderate-to-major TIS response at 16 weeks, meeting the registrational primary endpoint threshold
  • All 5 DM responders maintained IM-free response through latest follow-up as long as 1.5 years
  • First JDM patient achieved IM-free moderate TIS response at 16 weeks, maintained at 32 weeks; JDM to be included in 2H27 BLA submission
  • Systemic sclerosis announced as second pivotal indication; single-arm registrational study of ~25 patients with ILD expected to start in 4Q26

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access